Cancer drug developer Exelixis Inc. plans to sell 10 million shares of common stock
The South San Francisco-based company (NASDAQ: EXEL), which has centered its drug-development efforts around the cancer-fighting drug cabozantinib, said in a Securities and Exchange Commission filing Thursday that it will use net proceeds from the offering for research and development, capital expenditures, working capital and other purposes.
No comments:
Post a Comment